The global veterinary contract manufacturing market size was estimated at USD 4.0 billion in 2025 and is projected to reach USD 7.7 billion by 2033, growing at a CAGR of 8.6% from 2026 to 2033. The market is experiencing robust growth due to several key factors, including the rising strategic focus on contract manufacturing organization (CMO) core business models, increasing capacity expansion and investments in multi-species manufacturing facilities, growing demand for infrastructure development, a higher volume of outsourced manufacturing contracts, and a favorable regulatory environment. As animal health companies continue to expand their product portfolios and seek greater operational flexibility, contract manufacturing has become an increasingly important strategy for improving production efficiency, reducing capital expenditures, and accelerating time to market for veterinary pharmaceuticals, vaccines, and biologics.
The market is being driven by companies that are prioritizing CMO-focused business models to enhance operational efficiency, scalability, and specialized manufacturing capabilities. Animal health companies are increasingly shifting from in-house production to outsourcing arrangements, allowing them to concentrate on research and development, product commercialization, and portfolio expansion while leveraging the expertise and regulatory compliance capabilities of experienced manufacturing partners. This transition is further supported by the growing demand for complex veterinary biologics, active pharmaceutical ingredients (APIs), and companion animal therapeutics, all of which often require sophisticated production technologies and strict quality controls. For instance, in April 2026, Prange Pharma acquired an animal health manufacturing site from MSD Animal Health in Italy, significantly strengthening its contract manufacturing capabilities and strategic positioning within the contract development and manufacturing organization (CDMO) space. Such investments and acquisitions are helping expand production capacity, enhance service offerings, and support the continued growth of the veterinary contract manufacturing market.
Key Market Trends & Insights
• Europe held the largest revenue share of 31.1% of the global veterinary contract manufacturing industry in 2025, highlighting the region’s strong position in outsourced animal health production. This leadership is supported by a well-established pharmaceutical manufacturing infrastructure, stringent regulatory standards, and the presence of numerous animal health companies and specialized contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs). The region also benefits from significant investments in veterinary pharmaceuticals, vaccines, and biologics, along with a growing emphasis on quality assurance and regulatory compliance. These factors continue to drive demand for outsourced manufacturing solutions across Europe.
• Germany dominated the European region with the largest revenue share in 2025. The country’s leadership can be attributed to its advanced pharmaceutical manufacturing capabilities, highly skilled workforce, and strong focus on innovation in animal health products. Germany is home to several established CMOs and CDMOs that provide specialized services for veterinary pharmaceuticals, biologics, and active pharmaceutical ingredients (APIs). Its robust industrial base, strict adherence to Good Manufacturing Practice (GMP) standards, and strategic location within Europe further strengthen its role as a major hub for veterinary contract manufacturing.
• By product, the pharmaceuticals segment held the largest share of 48.1% of the market in 2025. This segment led the market due to the high demand for veterinary medicines used to prevent and treat diseases in both companion and production animals. Outsourcing pharmaceutical manufacturing allows animal health companies to access specialized formulation, scale-up, and regulatory expertise while reducing capital investment and operational complexity. The increasing development of anti-infectives, parasiticides, pain management drugs, and chronic disease treatments continues to support the segment’s dominant position.
• By animal, the production animal segment held the largest share of the market in 2025. This segment includes livestock such as cattle, poultry, swine, and sheep, which represent a substantial portion of global animal health spending. The large-scale use of veterinary pharmaceuticals and vaccines to improve productivity, maintain herd health, and prevent disease outbreaks in food-producing animals has driven significant demand for outsourced manufacturing services. Rising concerns about food safety and sustainable livestock production are further reinforcing the segment’s leading market position.
• By service, the manufacturing services segment held the largest market share in 2025. Manufacturing services encompass large-scale production, fill-finish operations, packaging, and quality control activities that are essential for commercializing veterinary products. Animal health companies increasingly rely on specialized manufacturing partners to ensure regulatory compliance, maintain product quality, and meet growing global demand efficiently. The critical role of these services in delivering scalable and cost-effective production solutions has enabled the manufacturing services segment to account for the largest share of the veterinary contract manufacturing market.
Looking for more specific insights? Customize this report to suite your business needs
Key Veterinary Contract Manufacturing Company Insights
Some of the key companies operating in the veterinary contract manufacturing market include Aenova Group, Grifols International, Labiana, Terumo Corporation (through Terumo BCT), Kela Health, Vetio Animal Health, and Parnell, among others. These companies offer a wide range of services, including formulation development, active pharmaceutical ingredient (API) manufacturing, biologics production, fill-finish operations, packaging, and regulatory support for veterinary pharmaceuticals and vaccines. Their capabilities enable animal health companies to outsource complex manufacturing activities while maintaining compliance with stringent quality and regulatory standards.
The veterinary contract manufacturing market is fragmented in nature, with numerous regional and specialized contract manufacturers competing on the basis of cost, technical expertise, production flexibility, and niche capabilities. In addition to large multinational contract development and manufacturing organizations (CDMOs), many smaller providers serve specific geographic markets or focus on particular dosage forms, species, or product categories. This competitive landscape encourages continuous investment in capacity expansion, advanced manufacturing technologies, and quality systems to attract new outsourcing contracts. As demand for veterinary pharmaceuticals, biologics, and companion and production animal therapeutics continues to grow, both global and regional manufacturers are expanding their service offerings to strengthen their market positions and meet the evolving needs of animal health companies worldwide.
Key Veterinary Contract Manufacturing Companies:
The following key companies have been profiled for this study on the veterinary contract manufacturing market.
• Aenova Group
• Grifols International
• Labiana
• Argenta Holdco Limited
• Kela Health
• Vetio Animal Health
• TriRx Pharmaceutical Services
• Parnell
• VetViva Richter GmbH
• Tecton Industries
• Ubio Biotechnology Systems Pvt Ltd
• Terumo Corporation (Terumo BCT)
• BioVenic
• Esco Aster Pte. Ltd
• Alicanto Vetcare
Grand View Research offers
√ Focused market intelligence reports on specific geographies or high-growth segments.
√ Extended forecast timelines for long-term planning.
√ Competitor Benchmarking and Supply Chain Analysis
√ Inclusion of regulatory and policy assessments.
√ Inclusion of custom data models, KPIs, or applications unique to your business
√ Specific high-impact Data Decks and Tables to support effective decision making
And much more…
Looking for a report customized to your requirements? Explore our Custom Research Offering
English
Arabic
French
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt